Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis. METHODS: Apolipoprotein E-deficient mice, a model of atherosclerosis, underwent uninephrectomy, subtotal nephrectomy or sham operation at 8 weeks of age and were treated with AST-120 after renal ablation. Atherosclerosis and its characteristics were assessed at 25 weeks of age. RESULTS: Uninephrectomy and subtotal nephrectomised mice had significantly increased acceleration of atherosclerosis. AST-120 treatment dramatically reduced the atherosclerotic burden in mice with kidney damage, while there was no beneficial effect in sham-operated mice. The benefit was independent of blood pressure, serum total cholesterol or creatinine clearance. AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content. Furthermore, AST-120 lessened aortic expression of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-1β messenger RNA. CONCLUSIONS: AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in animal models of renal dysfunction, the oral charcoal absorbent AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content (73) while attenuating monocyte inflammation (74).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Recent interest in lipid-independent risk predictors has identified inflammation as an important contributor to CVD in the general population [24, 25].”
BackgroundInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768 · cited 2×
“CKD dramatically increases atherosclerosis and cardiovascular events [1, 2].”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 2×
“also the most resistant to conventional lipid-lowering therapies [5].”
BackgroundKeith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., & Smith, D. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.659 · Cited by 1,684 · cited 1×
“Indeed, the risk of premature cardiovascular disease (CVD) death in patients with CKD is much higher than the risk of progressing to dialysis or transplantation [3, 4].”
BackgroundInflammatory Markers and the Risk of Coronary Heart Disease in Men and Women
Pai, J. K., Pischon, T., Ma, J., Manson, J. E., Hankinson, S. E., Joshipura, K., Curhan, G. C., Rifai, N., Cannuscio, C. C., Stampfer, M. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040967 · Cited by 1,174 · cited 1×
“Recent interest in lipid-independent risk predictors has identified inflammation as an important contributor to CVD in the general population [24, 25].”
BackgroundSelf-citationSarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000102971.85504.7c · Cited by 1,144
Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., & Massy, Z. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03980609 · Cited by 929 · cited 3×
“clinical findings showing that serum indoxyl sulfate is correlated with cardiovascular mortality in CKD patients [15] and that CKD patients treated with AST-120 before initiation of dialysis have significantly better 5-year survival after dialysis was begun compared with patients who did not receive this treatment bef…”
BackgroundResultInfluentialMenon, V., Greene, T., Wang, X., Pereira, A. A., Marcovina, S. M., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Sarnak, M. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00455.x · Cited by 417 · cited 1×
“This mechanism may be an especially relevant predictor of cardiovascular mortality at every stage of CKD [26, 27].”
Background
Cited by
Tang, W. H. W., Wang, Z., Fan, Y., Levison, B., Hazen, J. E., Donahue, L. M., Wu, Y., & Hazen, S. L. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.617 · Cited by 681
“In the setting of advanced renal diseases, direct binders have been reported to reduce levels of indoxyl sulfate, a tryptophan-based gut microbiome metabolite that has shown antiatherosclerotic effects in animal models (23).”
The contributory role of gut microbiota in cardiovascular disease
Tang, W. H. W., & Hazen, S. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72331 · Cited by 641
“…(72), and in animal models of renal dysfunction, the oral charcoal absorbent AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content (73) while attenuating monocyte inflammation (74).”
BackgroundZhang, L. S., & Davies, S. S. (2016) · Genome Medicine · doi:10.1186/s13073-016-0296-x · Cited by 500
“The oral charcoal adsorbent AST-120 binds indoles in the gut lumen and reduces plasma IndS levels, thereby reducing kidney damage and atherosclerosis associated with kidney injury [143].”
BackgroundLim, Y. J., Sidor, N. A., Tonial, N. C., Che, A., & Urquhart, B. L. (2021) · Toxins · doi:10.3390/toxins13020142 · Cited by 373
“In vivo, AST-120 has shown reno- and cardio-protective effects against uremic toxins [60,61].”
BackgroundAtherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?
Valdivielso, J. M., Rodríguez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortiz, A. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 305
Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis
Nagatomo, Y., & Tang, W. H. W. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.09.017 · Cited by 259
“Among them, indoxyl sulfate is a metabolite derived from dietary tryptophan [42] and is associated with the progression of renal dysfunction as well as vascular pathology by oxidative stress-induced modification of proinflammatory mediators [44].”
BackgroundSallée, M., Dou, L., Cerini, C., Poitevin, S., Brunet, P., & Burtey, S. (2014) · Toxins · doi:10.3390/toxins6030934 · Cited by 255
“Induction of atherosclerotic lesions in mice [52]”
BackgroundLiu, W.-C., Tomino, Y., & Lu, K.-C. (2018) · Toxins · doi:10.3390/toxins10090367 · Cited by 194
“This demonstrated that the use of AST-120 reduced the degree of vascular calcification [89].”
BackgroundVascular Incompetence in Dialysis Patients—Protein‐Bound Uremic Toxins and Endothelial Dysfunction
Jourde‐Chiche, N., Dou, L., Cerini, C., Dignat‐George, F., & Brunet, P. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.00925.x · Cited by 187
“In apolipoprotein E-deficient mice, AST-120 also lessens the extent of atherosclerosis induced by kidney injury (142).”
BackgroundCardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease
Moradi, H., Sica, D. A., & Kalantar-Zadeh, K. (2013) · American Journal of Nephrology · doi:10.1159/000351758 · Cited by 179
Ito, S., & Yoshida, M. (2014) · Toxins · doi:10.3390/toxins6020665 · Cited by 174
“AST-120 may be effective for the treatment of vascular and cardiac diseases in CKD patients, and has been shown to attenuate the development of atherosclerosis through the suppression of TNF-α, IL-1β, and MCP-1 expression in the aorta of nephrectomized apolipoprotein E-deficient mice [80].”
BackgroundIndoxyl Sulfate, a Uremic Endotheliotoxin
Lano, G., Burtey, S., & Sallée, M. (2020) · Toxins · doi:10.3390/toxins12040229 · Cited by 160
“Unfortunately, in these studies, the authors did not mention whether these effects were correlated with the reduction in IS blood concentrations [72,73].”
BackgroundCardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome
Lekawanvijit, S. (2018) · Toxins · doi:10.3390/toxins10090352 · Cited by 130
“AST-120 has been demonstrated to reduce PBUTs levels in association with improved renal function and renal pathologic changes [203–205], delay progression of atherosclerosis [206] and improved cardiac remodeling [141,142].”
BackgroundThe Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders
Assem, M., Lando, M., Grissi, M., Kamel, S., Massy, Z. A., Chillon, J., & Hénaut, L. (2018) · Toxins · doi:10.3390/toxins10070303 · Cited by 128
“In addition, uremic toxins such as IS are known to participate in the pathogenesis of stroke by amplifying atherosclerosis [46,201] and hypertension [29].”
BackgroundYamamoto, S., Yancey, P. G., Zuo, Y., Ma, L.-J., Kaseda, R., Fogo, A. B., Ichikawa, I., Linton, M. F., Fazio, S., & Kon, V. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.237198 · Cited by 115
Self-citationCrucial Role of the Aryl Hydrocarbon Receptor (AhR) in Indoxyl Sulfate-Induced Vascular Inflammation
Ito, S., Osaka, M., Edamatsu, T., Itoh, Y., & Yoshida, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34462 · Cited by 119
The gut microbiota and its relationship with chronic kidney disease
Plata, C., Cruz, C., Cervantes, L. G., & Ramírez, V. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02291-2 · Cited by 112
Yamamoto, S., Kazama, J. J., Omori, K., Matsuo, K., Takahashi, Y., Kawamura, K., Matsuto, T., Watanabe, H., Maruyama, T., & Narita, I. (2015) · Scientific Reports · doi:10.1038/srep14381 · Cited by 84
Self-citationYamamoto, S., Kazama, J. J., Wakamatsu, T., Takahashi, Y., Kaneko, Y., Goto, S., & Narita, I. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0056-9 · Cited by 77
“When the mice were treated with an oral charcoal adsorbent AST-120 after renal ablation, AST-120 treatment dramatically ameliorated the kidney damage-induced atherosclerosis [29].”
BackgroundSelf-citationWakamatsu, T., Yamamoto, S., Ito, T., Sato, Y., Matsuo, K., Takahashi, Y., Kaneko, Y., Goto, S., Kazama, J. J., Gejyo, F., et al. (2018) · Toxins · doi:10.3390/toxins10030124 · Cited by 77
“We previously showed that IS deposits in CKD-induced acceleration of atherosclerotic lesions [5] and reacts to macrophages directly, inducing inflammation and abnormal lipid handling [8], but the detailed mechanism is not completely understood.”
BackgroundSelf-citationExperimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice
Takamiya, Y., Fukami, K., Yamagishi, S., Kaida, Y., Nakayama, Y., Obara, N., Iwatani, R., Ando, R., Koike, K., Matsui, T., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs387 · Cited by 72
“Ccr (μL/min/g) = (urinary creatinine × urinary volume (μL/day)/plasma creatinine ×24 × 60)/body weight [11].”
BackgroundDeleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120
Six, I., Gross, P., Rémond, M. C., Chillon, J., Poirot, S., Drüeke, T. B., & Massy, Z. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.019 · Cited by 69
“[32] recently showed a reduction of CKD induced atherosclerosis in response to AST-120, using same ApoE / mouse model.”
MethodWiese, C. B., Zhong, J., Xu, Z., Zhang, Y., Solano, M. A. R., Zhu, W., Linton, M. F., Sheng, Q., Kon, V., & Vickers, K. C. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.023 · Cited by 65
“Subtotal 5/6 nephrectomy (5/6Nx) was performed under isoflurane inhalation anesthesia on 10–12 wk old female Apoe−/− mice, as previously described [18].”
MethodSelf-citationInnate Immunity System in Patients With Cardiovascular and Kidney Disease
Zoccali, C., & Mallamaci, F. (2023) · Circulation Research · doi:10.1161/circresaha.122.321749 · Cited by 66
Hamano, H., Ikeda, Y., Watanabe, H., Horinouchi, Y., Izawa‐Ishizawa, Y., Imanishi, M., Zamami, Y., Takechi, K., Miyamoto, L., Ishizawa, K., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx252 · Cited by 65
“7 groups and treated for three more weeks; specifically, a “normal diet” group and an “AST-120” group, in which the normal diet was supplemented with 5% AST-120, were established [13, 19].”
BackgroundMethodLekawanvijit, S., & Krum, H. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.273078 · Cited by 61
“2012a) and limiting or stabilizing atherosclerotic plaque in CKD mice with apolipoprotein E deficiency (Yamamoto et al. 2011).”
BackgroundLekawanvijit, S. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0749 · Cited by 58
Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome
Lekawanvijit, S., Kompa, A. R., & Krum, H. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00348.2015 · Cited by 54
“Table 2 Summary of studies on targeting production of protein-bound uremic toxins in cardiovascular and renal disease 209 210 Animal studies Clinical studies Protein restriction diet - Improved renal function and delayed progression of glomerulosclerosis as well as reduced serum and urine IS levels in a model of uremi…”
Novel drugs and intervention strategies for the treatment of chronic kidney disease
Heerspink, H. J. L., & de Zeeuw, D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12195 · Cited by 53
Matsuo, K., Yamamoto, S., Wakamatsu, T., Takahashi, Y., Kawamura, K., Kaneko, Y., Goto, S., Kazama, J. J., & Narita, I. (2015) · Toxins · doi:10.3390/toxins7083155 · Cited by 52
“However, absorbent oral charcoal ameliorated the accumulation of IS in the lesion and simultaneously reduced atherosclerosis [14].”
Self-citationThe gut microbiota in thrombosis
Khuu, M. P., Paeslack, N., Dremova, O., Benakis, C., Kiouptsi, K., & Reinhardt, C. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01070-6 · Cited by 44
“Administration of AST-120 in Apoe −/− mice with renal dysfunction reduced the deposition of indoxyl sulfate in aortic atherosclerotic lesions, and decreased the size and instability of atherosclerotic plaques 196 .”
Yamamoto, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1588-9 · Cited by 43
“Our research suggested that kidney injury-induced acceleration of atherosclerosis is associated with IS [31], the renin-angiotensin-aldosterone system [32], and peroxisome proliferator-activated receptor-γ [33].”
BackgroundSelf-citationTargeting protein-bound uremic toxins in chronic kidney disease
Niwa, T. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.829456 · Cited by 43
“AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation [83].”
BackgroundYamamoto, S., Zhong, J., Yancey, P. G., Zuo, Y., Linton, M. F., Fazio, S., Yang, H., Narita, I., & Kon, V. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.055 · Cited by 41
“To assess necrotic areas in atherosclerotic lesions, cryosections were stained with Harris H&E (SigmaeAldrich) as previously described [22,25,26].”
BackgroundMethodSelf-citationYamamoto, S., Fuller, D. S., Komaba, H., Nomura, T., Massy, Z. A., Bieber, B. A., Robinson, B. M., Pisoni, R. L., & Fukagawa, M. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa121 · Cited by 39
“Basic studies showed that IS induces acceleration of various systemic disorders, such as atherosclerosis and abnormal bone metabolism, in kidney-damaged animal models [6, 7].”
BackgroundSelf-citationThe effect of activated charcoal on adenine-induced chronic renal failure in rats
Ali, B. H., Za’abi, M. A., Ramkumar, A., Al‐Lawati, I., Waly, M. I., Beegam, S., Nemmar, A., Brand, S., & Schupp, N. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.12.038 · Cited by 39
“They have been shown to remove waste products such as urea, indoxyl sulfate (IS) and other urinary toxins, and augment the dialysis process (Schulman, 2012; Winchester and Ronco, 2010; Yamamoto et al., 2011).”
BackgroundTissue Factor, Thrombosis, and Chronic Kidney Disease
Oe, Y., & Takahashi, N. (2022) · Biomedicines · doi:10.3390/biomedicines10112737 · Cited by 35
“With regard to CVD complications, a basic study showed that AST-120 inhibited the progression of atherosclerosis in apolipoprotein E-deficient mice that underwent subtotal nephrectomy, suggesting an inhibitory effect on CVD events [91,92].”
BackgroundChao, C., & Lin, S. (2020) · Toxins · doi:10.3390/toxins12120812 · Cited by 33
Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis
Wakamatsu, T., Yamamoto, S., Yoshida, S., & Narita, I. (2024) · Toxins · doi:10.3390/toxins16060254 · Cited by 32
“AST-120 is indicated to stabilize atherosclerotic plaque [162].”
BackgroundSelf-citationTargeting Immunity in End-Stage Renal Disease
Baragetti, I., Essawy, B. E., & Fiorina, P. (2017) · American Journal of Nephrology · doi:10.1159/000458768 · Cited by 29
Cardiorenal Syndrome: Role of Protein-Bound Uremic Toxins
Lekawanvijit, S., & Krum, H. (2014) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2014.10.009 · Cited by 28
“Vascular End Points AST-120 has been demonstrated to alleviate atherosclerosis by limiting plaque extension, inflammation, and necrosis in a mice CKDmodel with apolipoprotein E-deficiency.(64) AST-120 also reduces hypercholesterolemia and”
BackgroundRyu, J., Yu, M., Lee, S., Ryu, D., Kim, S.-J., Kang, D., & Choi, K. B. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.4.942 · Cited by 27
“Treatment with AST-120 for 24 weeks ameliorates FMD in pre-dialysis CKD patients,(12) ED in CKD rat model,(25) and reduces the extent and instability of atherosclerosis in mouse renal injury models.(26) Recently, treatment with AST-120 for 3 months decreased serum cardiovascular biomarkers like malondialdehyde and int…”
Nakada, Y., Onoue, K., Nakano, T., Ishihara, S., Kumazawa, T., Nakagawa, H., Ueda, T., Nishida, T., Soeda, T., Okayama, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51292-9 · Cited by 25
Dietary Components, Microbial Metabolites and Human Health: Reading between the Lines
Guo, Y., Bian, X., Liu, J., Zhu, M. Q., Li, L., Yao, T., Tang, C., Ravichandran, V., Liao, P., Papadimitriou, K., et al. (2020) · Foods · doi:10.3390/foods9081045 · Cited by 24
“the intestinal lumen, and reduces the blood plasma indole sulfate levels, in turn decreasing kidney damage and atherosclerosis-related kidney injuries [61].”
BackgroundUremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications
Yamagami, F., Tajiri, K., Yumino, D., & Ieda, M. (2019) · Toxins · doi:10.3390/toxins11100597 · Cited by 21
“Treatment with AST-120 has been shown to ameliorate the following: endothelial dysfunction in CKD rats [78]; the extent and instability of atherosclerosis induced by kidney disease in apolipoprotein E-deficient mice [79]; flow-mediated vasodilation in pre-dialysis CKD patients [80]; and microvascular endothelial dysfu…”
BackgroundTsai, L.-T., Weng, T., Chang, T.-Y., Lan, K., Chiang, C., & Liu, S. (2023) · Antioxidants · doi:10.3390/antiox12111931 · Cited by 18
“Notably, recent studies have shown that AST-120 exhibits potential cardioprotective effects by reducing aortic IS deposition, attenuating atherosclerosis, and protecting the heart and kidneys [72].”
BackgroundMEDICAL AND ENVIRONMENTAL APPLICATIONS OF ACTIVATED CHARCOAL: REVIEW ARTICLE
Alkhatib, A. J., Alkhatib, A. J., & Zailaey, K. A. (n.d.) · Cited by 17
Lu, Y., Meng, L., Wang, X., Zhang, Y., Zhang, C., & Zhang, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167938 · Cited by 16
“Animal studies have demonstrated that AST-120 can effectively lower serum IS and pCS levels in CKD rats while delaying renal function deterioration [205–207].”
Hirakawa, H., Uchida, M., Kurabayashi, K., Nishijima, F., Takita, A., & Tomita, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232461 · Cited by 13
Gipson, G. T., Carbone, S., Wang, J., Dixon, D. L., Jovin, I. S., Carl, D. E., Gehr, T. W. B., & Ghosh, S. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.11.003 · Cited by 12
“White 10 (76) 9 (60) 10 (67) 1 (7) 3 (18)”
ALTUNKAYNAK-CAMCA, H. O., Karaismailoğlu, E., & Massy, Z. A. (2024) · Toxins · doi:10.3390/toxins16120544 · Cited by 11
Nagata, D., & Yoshizawa, H. (2020) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s287237 · Cited by 10
Peritoneal Dialysis Aggravates and Accelerates Atherosclerosis in Uremic ApoE −/− Mice
Kane, J., Vos, W. G., Bosmans, L. A., van Os, B. W., den Toom, M., Hoeksema‐Hackmann, S., Wit, D. M., Gijbels, M. J., Beckers, L., Grefhorst, A., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034066 · Cited by 8
Research progress on the relationship between IS and kidney disease and its complications
Gao, Y., Li, Y., Duan, X., Wang, Q., & Zhang, H. (2022) · International Urology and Nephrology · doi:10.1007/s11255-022-03209-1 · Cited by 8
Oral Charcoal Adsorbents Attenuate Neointima Formation of Arteriovenous Fistulas
Shih, Y.-C., Wu, C., Wang, S., Liou, J., Huang, P., & Tarng, D. (2020) · Toxins · doi:10.3390/toxins12040237 · Cited by 7
Adjusted Anion Gap Is Associated with Glomerular Filtration Rate Decline in Chronic Kidney Disease
Togawa, A., Uyama, S., Takanohashi, S., Shimasaki, M., Miyaji, T., Endo, H., & Fujigaki, Y. (2013) · Nephron Extra · doi:10.1159/000356461 · Cited by 7
Animal Models for Studying Protein-Bound Uremic Toxin Removal—A Systematic Review
Ahmed, S., de Vries, J. C., Lu, J., Stuart, M. H. V., Mihaila, S. M., Vernooij, R. W. M., Masereeuw, R., & Gerritsen, K. G. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713197 · Cited by 6
“Among mouse studies, one [39] did not report sex, one reported both sexes [69], and one reported females, but without information on plasma/serum IS data [70].”
BackgroundDoladé, N. G., Rayego‐Mateos, S., García-Carrasco, A., Guérin, M., Martín-Ventura, J. L., Ruiz‐Ortega, M., Tharaux, P., & Valdivielso, J. M. (2023) · Clinical Science · doi:10.1042/cs20230399 · Cited by 5
Cao, L., Fu, Q., Wang, B. H., Jin, W. Y., & Li, Z. (2014) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2014.07.001 · Cited by 4
Iindoxyl Sulfate, A Tryptophan Metabolite, Induces Nephro-Vascular Toxicity
Niwa, T. (2012) · Biotechnology & Biotechnological Equipment · doi:10.5504/50yrtimb.2011.0024 · Cited by 4
Novel Combination Therapy to Target Heart and Kidney
Lekawanvijit, S., & Krum, H. (2014) · Springer eBooks · doi:10.1007/978-3-319-09162-4_19 · Cited by 2
Rao, C., Zhou, Y., Han, L., Li, P., Geng, A., Zhong, Q., Zhou, J., He, K., & Zhou, F. (2026) · BMC Microbiology · doi:10.1186/s12866-025-04609-w · Cited by 1
“…metabolism) not only participates in renal dysfunction progression via modification by oxidative stress-induced pro-inflammatory mediators [30], but also exhibits direct toxicity to cardiomyocytes (inducing hypertrophy) and cardiac fibroblasts (inducing collagen synthesis) in vitro and in…”
Guo, K., Sun, M., Hu, S., Wang, X., Ji, X., Chen, Y., Cui, L., Liu, Z., Li, X., He, Y., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.12.026 · Cited by 1
Niwa, T. (2012) · Wiley eBooks · doi:10.1002/9781118424032.ch4 · Cited by 1
Therapeutic Removal of Uremic Toxins by Oral Sorbent
Niwa, T. (2012) · Wiley eBooks · doi:10.1002/9781118424032.ch23
Reducing Tryptophan Metabolites to Reduce Progression in Chronic Kidney Failure
Niwa, T. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391934-2.00015-1
Uremic Toxin-Related Systemic Disorders
Yamamoto, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-7793-2_4
Self-citationProximal Tubular Secretion, Cardiovascular Events, and Kidney Clearance of Medications
Chen, Y. (2020) · ResearchWorks at the University of Washington (University of Washington)
HUMAN GUT MICROBIOTA AND ITS EFFECTS ON HUMAN HEALTH IN NORMAL AND PATHOLOGICAL CONDITIONS
Munteanu, A. M., Cursaru, R., Guja, L., Carniciu, S., Borcan, A. M., & Popescu‐Spineni, D. (2017) · Romanian Medical Journal · doi:10.37897/rmj.2017.3.2
Айтбаев, К. А., Murkamilov, I. T., Абдилалимовна, М. Ж., Fomin, V. V., Kudaibergenova, I., Yusupova, T. F., & Yusupov, F. A. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-217-9-201-208
Abdullah, M. H., Shuid, A. N., Aziz, M. Y., Zabidi, M. A., Ramli, M. M., & Mohamed, R. (2025) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2025.105528
Ghani, A., Alkhawlani, M., Humaid, A., Thabet, A., & Ibrahim, H. (2025) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.20266915
Papel de BTLA en el eje cardio-renal
Masot, N. D. (2023) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
High sulphur activated carbon regeneration
Powell, C. (2023) · Nottingham ePrints (University of Nottingham)
Grzesiak, L. (2022) · theses.fr (ABES) · doi:10.70675/87cfdb2dz8503z4086z8654zcad10b50d0cb
山本, 卓. (2018) · Niigata medical journal
Yamamoto, S., Tanaka, T., Kitamura, N., Kawachi, M., Yokoseki, A., Wakasugi, M., Onodera, O., Endo, N., Wada, M., Satô, K., et al. (2026) · Toxins · doi:10.3390/toxins18100422
“Additionally, IS and PCS are known to promote vascular calcification and atherosclerosis [24,25].”
Self-citation张俊艳, Chen, Y., Tao, S., Zhou, M., Li, C., 饶莉, He, Y., & Chen, Z. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10189-6
Retention and toxicity of uremic solutes in chronic kidney disease.
Mutsaers, H. A. M. (2014) · Radboud Repository (Radboud University)
Metadata
- Authors
- Yamamoto, S., Zuo, Y., Ma, J., Yancey, P. G., Hunley, T. E., Motojima, M., Fogo, A. B., Linton, M. F., Fazio, S., Ichikawa, I., & Kon, V.
- Affiliations
- Vanderbilt University Medical Center (US)
- Tokai University (JP)
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-18
- Volume
- 26
- Issue
- 8
- Pages
- 2491-2497
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC3203394
- OpenAlex
- W2112575385
- Cited by
- 74
- References
- 46
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 6 · 2014: 10 · 2013: 4 · 2012: 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL057986, R01HL087061)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 44757, U24DK059637, DK59637-01, P50DK044757)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- AST-120, atherosclerosis, chronic kidney disease, uremic toxins, indoxyl sulfate, ApoE-deficient mice, unilateral nephrectomy, subtotal nephrectomy, plaque stability, plaque necrosis, vascular inflammation, MCP-1, TNF-α, IL-1β
- MeSH terms
- Administration, Oral, Animals, Apolipoproteins E, Carbon, Charcoal, Female, Immunoenzyme Techniques, Kidney Diseases, Kidney Function Tests, Mice, Inbred C57BL, Oxides, RNA, Messenger, Tumor Necrosis Factor-alpha, Mice, Knockout, Chemokine CCL2, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Interleukin-1beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.